Mathias Winkler

Consultant Urological Surgeon

Imperial Prostate, Division of Surgery, Department of Surgery and Cancer; and Department of Urology; Imperial College London, Charing Cross Hospital, London.

Latest Contribution

Map showing global portfolio of randomised trials offering cytoreductive surgery in de novo synchronous metastatic prostate cancer.

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Prostagram images

MRI screening for prostate cancer: a step towards a ‘prostagram’

7 January 2020 | | URO - Urologic Oncology, URO - Technology

The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...